Levothyroxine for Children With Euthyroid Sick Syndrome
NCT ID: NCT01631305
Last Updated: 2014-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
80 participants
INTERVENTIONAL
2012-01-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism
NCT02374593
Comparison of Levothyroxine Formulations in the Treatment of Congenital Hypothyroidism
NCT06724224
Antithyroid Drug Treatment of Thyrotoxicosis in Young People
NCT01436994
Prospective Evaluation of OptiThyDose
NCT06864351
TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients
NCT05316922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Levothyroxine
3 mcg/kg/day
Levothyroxine
3 mcg/kg/day
Control
Calcium magnesia.
Calcium magnesia
Placebo.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levothyroxine
3 mcg/kg/day
Calcium magnesia
Placebo.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to pediatric intensive care unit.
* TSH and thyroid hormones below age specific levels.
Exclusion Criteria
* Brain death.
* Gut conditions that contraindicate oral route.
* Readmissions to intensive care unit.
1 Month
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sinaloa Pediatric Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jesús Javier Martínez-García
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jesus J Martinez, MD
Role: STUDY_CHAIR
Sinaloa Pediatric Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sinaloa Pediatric Hospital
Culiacán, Sinaloa, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Sinaloa Pediatric Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HPS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.